Atenolol Dosing for Pediatric Systemic Hemangioma
For infantile hemangiomas requiring systemic treatment, propranolol—not atenolol—should be your first-line agent at 2-3 mg/kg/day, as it is the only FDA-approved beta-blocker for this indication and demonstrates superior complete response rates. 1
However, if you specifically need to use atenolol (e.g., due to propranolol intolerance or contraindications), the evidence-based dosing is 1 mg/kg/day given as a single daily dose. 2, 3
Why Propranolol Should Be First-Line
The 2019 American Academy of Pediatrics clinical practice guideline establishes propranolol as the standard of care for infantile hemangiomas (IH) requiring systemic therapy 1. The evidence is compelling:
- Dosing: Start at 1 mg/kg/day, titrate to target dose of 2-3 mg/kg/day divided twice daily
- Initiation: Begin with 0.6 mg/kg twice daily, increase over 2 weeks to maintenance of 1.7 mg/kg twice daily (3.4 mg/kg/day total) per FDA approval 1
- Duration: Minimum 6 months, ideally continue until at least 12 months of age to minimize rebound (10-25% risk) 1
- Administration: Give with or after feeds; hold doses during illness/vomiting to prevent hypoglycemia 1
When to Consider Atenolol Instead
Atenolol may be appropriate as an alternative when:
- Propranolol causes intolerable side effects (sleep disturbances, bronchial hyperreactivity, agitation)
- Patient has contraindications to non-selective beta-blockade
- Propranolol is unavailable
Critical caveat: A 2023 meta-analysis found propranolol achieves significantly higher complete response rates than atenolol (85.4% vs 73.3%, P=0.0004) 4. You're trading efficacy for tolerability.
Atenolol Dosing Protocol (When Used)
Dose: 1 mg/kg/day as a single daily dose 2, 3
Practical implementation:
- Start at 1 mg/kg/day (no titration needed unlike propranolol)
- Adjust monthly for weight gain 3
- Continue for 24 weeks minimum 2
- Monitor at weeks 1,4,8,12,16,20, and 24 2
Expected response timeline:
- Growth cessation: 93.4% by week 4 2
- Ulcer healing: Average 5.5 weeks 2
- Excellent response (complete/near-complete resolution): 56.5% at 24 weeks 2
Safety Comparison: Atenolol vs Propranolol
Atenolol's β1-selectivity and hydrophilicity theoretically reduce side effects:
Atenolol adverse events (pooled rate 26%):
- Most common: Diarrhea, agitation, sleep disturbance 2
- No reported cases of hypoglycemia, bronchospasm, bradycardia, or hypotension in treatment studies 2, 5
Propranolol has 2.7× higher odds of adverse events (OR 2.70,95% CI 1.90-3.84) 4, including:
- Significantly more agitation (P=0.0245) 4
- Significantly more bronchial hyperreactivity (P<0.0001) 4
- Hypoglycemia risk requiring feeding precautions 1
Among 44 patients switched from propranolol to atenolol due to adverse events, 90.9% responded successfully to atenolol 5.
Critical Monitoring Requirements
Regardless of which beta-blocker you choose:
Pre-treatment evaluation:
- MRI/MRA of head and neck (rule out PHACE syndrome)
- Echocardiography
- Baseline vital signs and glucose 1
Ongoing monitoring:
- Heart rate and blood pressure at each visit
- Assessment for bradycardia, hypotension
- Evaluation for sleep disturbances, respiratory symptoms
- Renal function (atenolol is renally excreted) 6
Special Populations Requiring Dose Adjustment
PHACE syndrome or high-risk patients: Use lowest effective dose, slow titration, consider three-times-daily dosing, co-manage with pediatric neurology 1
Renal impairment (applies to atenolol specifically): The FDA label provides adult dosing adjustments, but pediatric data are limited. Atenolol accumulates when creatinine clearance <35 mL/min/1.73m² 6. Exercise caution and consider dose reduction.
The Bottom Line Algorithm
- First choice: Propranolol 2-3 mg/kg/day (superior efficacy) 1, 4
- If propranolol not tolerated: Switch to atenolol 1 mg/kg/day (90.9% response rate in switchers) 5
- If starting with atenolol: Accept 12% lower complete response rate but significantly fewer adverse events 4, 7
- Duration: Continue until at least 12 months of age to minimize rebound 1
- Monitor closely: Both agents require cardiovascular and metabolic surveillance
The evidence clearly favors propranolol for efficacy, but atenolol represents a reasonable, evidence-based alternative when propranolol cannot be used, with the specific dose of 1 mg/kg/day once daily.